Reduction of serum Interleukin-1-like activity after treatment with XXXX .

@entity28895 @entity19 @entity35616 @entity5003 @entity5478 @entity619 @entity134 @entity230
The ability of @entity230 to modulate the appearance of Interleukin-1( @entity5003 ) in vivo was evaluated in a model of endotoxin shock. High levels of @entity5003 were found in serum from A/J @entity19 which were sensitized with @entity5478 and challenged with bacterial lipopolysaccharide (LPS). The factor appeared in the serum 2-4 hours after LPS challenge and was dependent on the period of @entity5478 sensitization and the dose of LPS. Treating the @entity19 with @entity619 prior to LPS challenge resulted in significantly lower thymocyte proliferative activity in the serum. Three experiments demonstrated that this reduced activity reflects a decrease in @entity28895 ) The reduced activity was not due to the presence of proliferation inhibitors since mixing the serum from @entity619 -treated @entity19 with purified @entity5003 or adding the equivalent amount of @entity134 directly to thymocyte cultures did not reduce the degree of proliferation. 2) When the serum was fractionated by gel filtration, the proliferative activity for both control and @entity134 treated sera eluted at 10-16 kilodaltons; however, the activity was nearly 50% less in the sample from @entity134 -treated @entity19 . 3) In addition to thymocyte proliferative activity, @entity5003 induces an increase in the serum titer of the acute phase protein known as serum amyloid A. Both serum- and gel-purified samples were able to induce the @entity35616 , but again the samples from @entity134 -treated @entity19 were much less active. We conclude that the factor produced in vivo has the properties of @entity5003 and that the serum titre of the factor is reduced by @entity619 treatment.
